On May 25, 2023, HC Wainwright & Co. issued a Buy recommendation for Kamada (NASDAQ:KMDA) which was reiterated in a report by Fintel. The average one-year price target for Kamada, as of May 11, 2023, is 12.75, which represents a potential upside of 136.11% from its current closing price of 5.40.
Kamada is a global specialty plasma-derived biopharmaceutical company with a portfolio of commercially available products, a strong pipeline, and top-notch manufacturing capabilities. The company aims to deliver profitable growth, given its current commercial products, plasma-derived development pipeline, and manufacturing expertise while transforming itself into a vertically integrated plasma-derived firm. Its top two products are GLASSIA® and KEDRRAB® which Kamada markets in the U.S. and in other countries through local distributors. KEDRAB is an FDA-approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment.
54 funds or institutions have reported positions in Kamada, with a total of 6,462K shares. However, the average portfolio weight of all funds dedicated to KMDA is at 0.01%, a decrease of 22.38%.
The firm’s lead shareholder is FIMI Opportunity Fund, which beneficially owns about 21% of the outstanding ordinary shares.
Disclaimer: Any views or opinions expressed in this report are solely those of the author and do not necessarily represent those of Nasdaq, Inc.